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1  | BACKGROUND
Intellectual disability is characterized by deficits in intellectual 
(IQ <70) and adaptive functioning presenting before 18 years 
of age, and has multiple aetiologies (American Psychiatric 
Association, 2013). People with intellectual disabilities have an 
increased risk of developing chronic somatic, psychiatric and 
psychological disorders (Häβler, Thome, & Reis, 2015), and often 
have multiple health conditions. As a result, a combination of 
medications is used over a long period of time to treat these dif‐
ferent conditions.
Polypharmacy, defined as the concurrent use of five or more 
medications (Stortz, Lake, Cobigo, Ouellette‐Kuntz, & Lunsky, 2014), 
is common among people with intellectual disabilities. A recent large‐
scale Dutch study, the “Healthy Ageing and Intellectual Disability” 
(HA‐ID) study (Evenhuis & Hermans, 2012), reported polypharmacy 
in 40% of people with intellectual disabilities aged 50 years or over. 
A literature review in 2014 (Stortz et al., 2014) described the prev‐
alence of polypharmacy among elderly people with intellectual dis‐
abilities, ranging from 11% to 60%, depending on the selection of the 
study sample. The prevalence of polypharmacy has been reported to 
be higher for people with intellectual disabilities living in residential 
 
Received: 6 April 2018  |  Revised: 21 December 2018  |  Accepted: 30 January 2019
DOI: 10.1111/jar.12580
R E V I E W
Effectiveness of medication reviews in identifying and reducing 
medication‐related problems among people with intellectual 
disabilities: A systematic review
Amal Nabhanizadeh1  |   Alyt Oppewal1  |   Fleur Heleen Boot2 |   
Dederieke Maes‐Festen1
1Intellectual Disability Medicine, 
Department of General Practice, Erasmus 
MC University Medical Centre Rotterdam, 
Rotterdam, The Netherlands
2Department of Psychology, Maynooth 
University, Maynooth, Ireland
Correspondence
Amal Nabhanizadeh, Intellectual Disability 
Medicine, Department of General Practice, 
Erasmus MC University Medical Centre 
Rotterdam, Rotterdam, The Netherlands.
Email: a.nabhanizadeh.1@erasmusmc.nl
Funding information
Koraal Groep Sittard, Limburg, Netherlands; 
's Heeren Loo Amersfoort, Utrecht, 
Netherlands
Abstract
Background: Polypharmacy is common in people with intellectual disabilities. Using 
multiple medication may lead to unintended medication‐related problems (MRPs). 
Medication review may serve as a tool to reduce MRPs. This systematic review as‐
sessed the scientific evidence for the effectiveness of medication reviews in identify‐
ing and reducing MRPs in people with intellectual disabilities.
Method: Literature databases were searched up to August 2017. Studies were se‐
lected that included the effect of medication reviews on identifying and/or reducing 
MRPs in people with intellectual disabilities with no restriction of type of medication, 
age and level of intellectual disabilities.
Results: The eight studies that fulfilled the inclusion criteria report that systematic 
medication reviews appear to assist in the identification and reduction of MRPs.
Conclusion: There is a lack of studies about the effect of medication reviews on iden‐
tification and reduction of MRPs, especially health outcomes for people with intel‐
lectual disabilities. Further studies with long‐term follow‐up are needed.
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settings compared to those living in the community, independently, 
or with family (McCarron et al., 2011).
Polypharmacy increases the risk of medication prescription er‐
rors (Zaal, Kaaij, Evenhuis, & Bemt, 2013) and inappropriate medi‐
cation prescribing (prescribing medications that pose more risk than 
potential benefits; Beers, 1997). In addition, medication may have 
potential side effects and interactions with other medications used 
(Scheifes, Egberts, Stolker, Nijman, & Heerdink, 2016; Stortz et al., 
2014). Therefore, with polypharmacy, the chance for medication‐
related problems (MRPs) is higher (Clyne, Bradley, Hughes, Fahey, 
& Lapane, 2012). According to the Pharmaceutical Care Network 
(PCNE), an MRP is “an event or circumstance involving medication 
therapy that actually or potentially interferes with desired health 
outcomes” (Pharmaceutical Care Network Europe, 2017). Studies 
(Leendertse, Egberts, Stoker, van den Bemt, & HARM Study Group, 
2008; Passarelli, Jacob‐Filho, & Figueras, 2005) found an increased 
risk of medication‐related hospital admissions in elderly patients as 
a consequence of inappropriate medication prescribing, and nearly 
half of those cases would have been amenable (Leendertse et al., 
2008). Polypharmacy can lead to increased mortality in the elderly 
living at home (Jyrkka, Enlund, Korhonen, Sulkava, & Hartikainen, 
2009; Roberts et al., 2001) and among people in nursing homes 
(Onder et al., 2013). MRPs were frequently seen in people with in‐
tellectual disabilities with polypharmacy, and they have been found 
to be more prevalent with increasing age (Haider, Ansari, Vaughan, 
Matters, & Emerson, 2014). Polypharmacy has also been found to 
be a strong predictor for mortality in older adults with intellectual 
disabilities over a 5‐year follow‐up period (Schoufour et al., 2018).
Systematic medication reviews have been introduced as a proce‐
dure to optimize medication use and reduce MRPs. The used defini‐
tion of a medication review is “a structured, critical examination of a 
patient's medicines with the objective of reaching an agreement with 
the patient about treatment, optimizing the impact of medicines, 
minimizing the number of MRPs and reducing waste” (Shaw, Seal, & 
Pilling, 2002). Studies including elderly patients with polypharmacy 
showed that MRPs were reduced through identification by medica‐
tion reviews and starting an alternate medication regime based on 
that (Holland et al., 2008; Lenander, Elfsson, Danielsson, Midlov, & 
Hasselstrom, 2014; Vinks, Egberts, Lange, & Koning, 2009).
Medication reviews are often performed by a multidisciplinary 
team including a medical doctor and pharmacist (Bell, McLachlan, 
Aslani, Whitehead, & Chen, 2005; Costa et al., 2015; Gallagher 
et al., 2011; Holland et al., 2008; Lenander et al., 2014; Liu et al., 
2012; Rubio‐Valera, Chen, & O'Reilly, 2014; Vinks et al., 2009; Wolf 
et al., 2015).It has been found that the multidisciplinary structured 
medication reviews that included a pharmacist improved the appro‐
priateness of therapy and medication safety in psychiatric patients 
(Rubio‐Valera et al., 2014; Wolf et al., 2015) in comparison with med‐
ication reviews without a pharmacist.
A recent narrative review (O'Dwyer, Mestrovic, & Henman, 
2015) for people with intellectual disabilities explored the role and 
contribution of pharmacists to the care of people with intellectual 
disabilities as part of multidisciplinary teams. The authors suggested 
that pharmacists have a positive contribution to the medication re‐
view team, but limited published evidence to support this notion is 
available.
In elderly patients with polypharmacy (Holland et al., 2008; 
Lenander et al., 2014; Vinks et al., 2009) and in psychiatric patients 
(Rubio‐Valera et al., 2014; Wolf et al., 2015), medication reviews have 
identified MRPs, and with the proposed drug adaptations MRPs de‐
creased. However, the effect of medication reviews for people with 
intellectual disabilities and polypharmacy is still unknown. This sys‐
tematic review was performed to assess the effectiveness of medi‐
cation reviews in identifying and reducing MRPs among people with 
intellectual disabilities.
2  | METHODS
The Preferred Reporting Items for Systematic Reviews and Meta‐
Analyses (PRISMA) statement was used as the basis for this sys‐
tematic review (Moher, Liberati, Tetzlaff, Altman, & PRISMA Group, 
2009).
2.1 | Search method
A comprehensive literature search of the electronic library data‐
bases PubMed, MEDLINE, EMBASE, Cumulative Index to Nursing 
and Allied Health Literature (CINAHL), the Cochrane Library, Google 
Scholar and Web of Science was performed. These databases were 
searched until August 2017. Search terms used for each database 
included: “learning disabilities,” “intellectual disabilities,” “mental 
retardation,” “developmental disabilities,” “learning difficulties” and 
“pharmacist intervention,” “medication review,” “drug use utiliza‐
tion.” Subject headings and truncated keywords related to pharmacy 
and medication management were used (See Appendix 1 for the full 
search strategy). Search strategies did not employ any restriction in 
time (year) of publication or study design. To identify as many stud‐
ies as possible, the PubMed and EMBASE function “similar studies” 
was used. And the reference lists of included studies were screened.
2.2 | Selection of studies
2.2.1 | Eligibility criteria
The following inclusion and exclusion criteria were employed.
Inclusion criteria
• Study sample with participants with intellectual disabilities, no 
restrictions on levels of intellectual disabilities, ages and gender.
• Study sample with participants who used medications for chronic 
conditions.
• Published in English or Dutch.
• Studies regarding the effect of pharmacist‐led medication reviews 
and/or clinical/general physician‐led medication reviews on iden‐
tifying and/or reducing MRPs.
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• Studies regarding comprehensive medication reviews of all 
medications or limited to certain medication groups were both 
included.
Exclusion criteria
• Reviews, editorial letters, comments.
• No full text available.
Titles and abstracts were screened independently by two authors 
(AN and FB) for eligibility and relevance, and selected for full‐text read‐
ing. Full text of the potential eligible studies was read using the inclu‐
sion and exclusion criteria mentioned above after which a decision was 
made regarding inclusion. Disagreement between the two authors was 
resolved via a consensus discussion.
2.3 | Quality assessment
The Standard Quality Assessment Criteria for Evaluating Primary 
Research Papers from a Variety of Fields (Kmet, Lee, & Cook, 2004) 
was used to assess the quality of the included studies. This tool con‐
tains quality criteria for both quantitative and qualitative studies. 
In this tool, quality is defined as “the extent to which the design, 
conduct and analyses minimized errors and biases.” The quality of 
all studies was independently assessed by two authors (AN and FB).
F I G U R E  1   Flow diagram of study 
selection process [Colour figure can be 
viewed at wileyonlinelibrary.com]
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The individual criteria were scored with a 2 for “yes,” 1 for “par‐
tial” and 0 for “no.” The sum of the scores on the applicable criteria 
divided by the maximum possible score on the applicable criteria 
gave the relative ranking of the study in the range 0–1 (low to high 
quality). Disagreement was resolved in a consensus discussion.
2.4 | Data extraction
The first author (AN) extracted the data from all included studies. 
Extracted data included information regarding the aim, study design, 
study population, type of medication review and outcome measures.
3  | RESULTS
3.1 | Search and selection strategy
A total of 1,277 studies were identified through the literature 
search. After deduplication, 759 studies remained, of which 35 
were selected based on title and abstract. Of these 35 studies, 30 
were excluded based on the exclusion criteria (review studies, MRPs 
not studied, editorial letters or not available in full text). Five stud‐
ies were included (Brašić, Furman, Conte, Baisley, & Jaslow, 2000; 
McKee, 1994; Scheifes et al., 2016; Thomsen, Rossing, Trier, Faber, & 
Herborg, 2014; Zaal et al., 2016). Through reference lists, one other 
study (Zaal et al., 2013) was included. Two other studies (Berchou, 
1982; Hancock, Weber, Kaza, & Her, 1991) were included through 
the literature search engine marked as similar studies. This resulted 
in a total of eight included studies (Berchou, 1982; Brašić et al., 2000; 
Hancock et al., 1991; McKee, 1994; Scheifes et al., 2016; Thomsen et 
al., 2014; Zaal et al., ) (Figure 1).
3.2 | Study characteristics
Tables 1 and 2 present the characteristics of the included stud‐
ies. Four studies were performed in the United States of America 
(Berchou, 1982; Brašić et al., 2000; Hancock et al., 1991; McKee, 
1994), three in the Netherlands (Scheifes et al., 2016; Zaal et al., ) 
and one in Denmark (Thomsen et al., 2014). Three studies (Berchou, 
1982; Hancock et al., 1991; McKee, 1994) were over 20 years old, 
and the other five were published in the past 18 years (Brašić et al., 
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2000; Scheifes et al., 2016; Thomsen et al., 2014; Zaal et al., ). One 
study was cross‐sectional (Zaal et al., 2013), two were explorative 
pilot studies (Thomsen et al., 2014; Zaal et al., 2016), three were lon‐
gitudinal studies with a prospective design (Berchou, 1982; Hancock 
et al., 1991; McKee, 1994) and two were descriptive studies (Brašić 
et al., 2000; Scheifes et al., 2016) (Table 1). Seven studies were quan‐
titative (Berchou, 1982; Brašić et al., 2000; Hancock et al., 1991; 
McKee, 1994; Scheifes et al., 2016; Zaal et al., ), and one study was 
both quantitative and qualitative (Thomsen et al., 2014).
The quality of the eight studies ranged from 0.34 to 0.86, from a 
possible maximum score of 1 (Table 2).
3.3 | Study participants and study setting
Four studies included people with all levels of intellectual disabilities 
and all ages (Berchou, 1982; Brašić et al., 2000; Zaal et al., 2016). 
Two studies (Brašić et al., 2000; Thomsen et al., 2014) did not specify 
participant's characteristics such as age and/or level of intellectual 
disabilities. Two studies included people with both intellectual dis‐
abilities and behavioural disorders (Scheifes et al., 2016; Thomsen 
et al., 2014). One study only included people over 50 years of age, 
with polypharmacy (Zaal et al., 2013). All participants of the included 
studies lived in residential settings.
3.4 | Medication review team and review method
Medication reviews differed in used methodology, composition of 
the teams, institution types, study time and included pharmacy ser‐
vice (e.g., community pharmacy or clinical pharmacist).
Six of the included studies reviewed all medications (Berchou, 
1982; McKee, 1994; Scheifes et al., 2016; Thomsen et al., 2014; Zaal 
et al., ), while two studies only reviewed psychotropics and anticon‐
vulsants (Brašić et al., 2000; Hancock et al., 1991; See Table 1).
All studies were performed in multidisciplinary settings by a team 
that consisted of a pharmacist and medical staff or caregivers. Three 
of the studies included a hospital pharmacist (Brašić et al., 2000; 
Scheifes et al., 2016; Zaal et al., 2013), and five studies included a 
community pharmacist (Berchou, 1982; Brašić et al., 2000; Hancock 
et al., 1991; McKee, 1994; Zaal et al., 2016). A multidisciplinary med‐
ication review took more time when more professionals participated 
(Scheifes et al., 2016; Zaal et al., 2016). Two studies (Berchou, 1982; 
Zaal et al., 2016) noted that the initial medication reviews per patient 
required more time than subsequent reviews.
In one study (Berchou, 1982), medical staff and caregivers were 
specifically trained to identify MRPs of psychotherapeutic agents. 
The authors suggested that the training could contribute to the 
quality of the input that the caregivers could provide during the 
medication reviews, and enhancing the effectiveness of the medi‐
ation reviews. In another study (Hancock et al., 1991), pharmacists 
provided, besides medication reviews, a combination of medication 
monitoring, patient education and patient follow‐up. Two studies 
(Berchou, 1982; McKee, 1994) provided education during the medi‐
cation reviews to improve knowledge of the caregivers.
Four studies (Brašić et al., 2000; McKee, 1994; Scheifes et al., 
2016; Zaal et al., 2016) described how medication reviews were per‐
formed and which steps were involved. One study (Scheifes et al., 
2016) used three main steps for identifying and reducing MRPs in 
structured medication reviews: (a) Review current medication and 
identify potential MRPs, (b) Define actual MRPs and formulate a new 
care plan and (c) Execute and monitor new care plan, evaluate exe‐
cuted and non‐executed actions. Another study (McKee, 1994) used 
the “Drug Regimen Review by Objective” method. This method is 
used to assure each medication has a clear indication throughout 
the therapy, continuous monitoring and avoid polypharmacy. In one 
study (Brašić et al., 2000), the pharmacist and the clinical reviewer 
would evaluate monthly to ensure the medication doses were within 
the usual therapeutic range. Another study (Zaal et al., 2016) used 
the Systematic Tool to Reduce Inappropriate Prescribing (STRIP) 
method in five steps which includes the existing methods Screening 
Tool to Alert doctors to Right Treatment (START) and the Screening 
Tool of Older Peoples Prescriptions (STOPP). The STRIP method is 
the key point addressed in the guideline “polypharmacy in the ageing 
population” in the Netherlands for older patients with polypharmacy 
in the general population to identify MRPs.
3.5 | Identification and reduction of MRPs
All of the included studies (Berchou, 1982; Brašić et al., 2000; Hancock 
et al., 1991; McKee, 1994; Scheifes et al., 2016; Thomsen et al., 2014; 
Zaal et al., ) focused on the identification of MRPs. The majority of the 
studies (Berchou, 1982; Hancock et al., 1991; McKee, 1994; Scheifes 
et al., 2016; Zaal et al., 2016) focused on reduction of MRPs.
3.5.1 | Identifying MRPs
Eight included studies reported that medication reviews performed 
by multidisciplinary teams could identify MRPs.
Identified MRPs in the included studies were side effects 
(Hancock et al., 1991; McKee, 1994; Scheifes et al., 2016; Thomsen 
et al., 2014; Zaal et al., 2016), errors in the administration of psy‐
choactive medication (Brašić et al., 2000), medication prescription 
without clear diagnosis (off‐label) or current indication (Berchou, 
1982; Scheifes et al., 2016; Zaal et al., ), prescribing errors such as 
incomplete or unreadable orders (Brašić et al., 2000; Zaal et al., ) and 
overprescription of psychotropic medications (high doses or exces‐
sive number of doses).
One study (Scheifes et al., 2016) did not describe any side effects 
but noted that underreporting of side effects and wrong interpre‐
tation of side effects could potentially have led to missing MRPs. In 
the study that identified errors in the administration of psychoactive 
medication (Brašić et al., 2000), a procedure was developed to iden‐
tify MRPs as part of the medication review to verify that the clients 
at the facility did not receive excessive doses of medications and 
that the sum of the medications of the same class did not exceed 
safe levels. This study recommends a monthly medication review to 
identify MRPs.
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Three studies reported the prevalence of MRPs that were found 
by the medication reviews; 34% (Scheifes et al., 2016), 47% (Zaal et 
al., 2013) and 100% (Zaal et al., 2016).
3.5.2 | Reducing MRPs
Four out of eight included studies (Hancock et al., 1991; McKee, 
1994; Scheifes et al., 2016; Thomsen et al., 2014) found that medi‐
cation reviews can minimize side effects such as extrapyramidal 
symptoms (tardive dyskinesia) (Hancock et al., 1991). Data extracted 
from these studies indicate that medication reviews led to changes 
in medication regimen and a general decrease in medication dosage. 
None of the studies described how the side effects of the medica‐
tions were measured.
4  | DISCUSSION
To our knowledge, this is the first systematic review concerning the 
effect of medication reviews on the identification and reduction of 
MRPs for people with intellectual disabilities. This systematic review 
examined the evidence from eight studies, predominantly conducted 
in the United States and Europe, reported between 1982 and 2017.
The overall finding of this review is that systematic medication 
reviews performed by a multidisciplinary team appear to assist in the 
identification and reduction of MRPs. However, limited evidence is 
available regarding the impact of medication reviews on the identifi‐
cation and reduction of MRPs in people with intellectual disabilities, 
to draw firm conclusions.
Many studies in general practice settings, the elderly and psy‐
chiatric patients describe medication reviews as an effective tool for 
identification and reduction of MRPs (Bell et al., 2005; Blenkinsopp, 
Bond, & Raynor, 2012; Mao, Vu, Xie, Chen, & Tang, 2015). The re‐
sults of this review seem to support this finding for people with in‐
tellectual disabilities.
4.1 | Client population
All studies included people living in residential care settings. People 
with intellectual disabilities living at home receiving their main care 
of a general physician were not included. This limits the generaliza‐
bility of the results of this review. It could be argued that medication 
of people who do not live in residential settings might be less often 
reviewed, increasing the chance of missing MRPs.
4.2 | Review team
All studies used a multidisciplinary team including a pharmacist. The 
actual team composition varied in all of the included studies but iden‐
tifying the optimal team composition was not part of the objectives.
The majority of included studies (Berchou, 1982; Brašić et 
al., 2000; Hancock et al., 1991; McKee, 1994; Scheifes et al., 
2016; Thomsen et al., 2014; Zaal et al., 2016) support the role of 
pharmacists in optimizing medication reviews. According to these 
studies, a pharmacist has more detailed knowledge of medications 
and a pharmacist can have a positive role in improving medication 
use. One study (Berchou, 1982) that included caregivers in the med‐
ication review had given specific training regarding identification of 
medication side effects to these caregivers. Other studies did not 
mention special education for the review process. Even though the 
studies were not designed to evaluate the composition of the review 
team and the relative contribution of the team members, the multi‐
disciplinary nature of the team is expected to be important. It could 
be speculated that addition of individual members such as a psychol‐
ogist or behavioural scientist on the multidisciplinary team can con‐
tribute to successful reduction in off‐label psychotropic medication 
in people with intellectual disabilities after the medication review.
The articles found with this systematic review did not report on 
international policies regarding multidisciplinary medication reviews.
In the Netherlands, policymakers believe that a multidisciplinary 
medication review is an important tool to optimize medication use 
and safety. Since 2010, annual medication reviews with a pharmacist 
are mandatory by order of the healthcare inspectorate (Inspectie 
voor de Gezondheidszorg IGZ) (Inspectie voor de Gezondheidszorg, 
2010). Therefore, multidisciplinary medication review teams includ‐
ing physician and pharmacist should be present in all care organiza‐
tions for people with intellectual disabilities in the Netherlands.
4.3 | Identification and reduction of MRPs
4.3.1 | Identification of MRPs
Inappropriate medication prescription can lead to MRPs. The studies 
in this review show that MRPs can be identified with a medication 
review. Some studies focused mainly on medication side effects, lack 
of indication, contraindication, medication interactions or prescrib‐
ing errors. This underlines the need to periodically perform medica‐
tion reviews, as an important tool for clinical practitioners to identify 
MRPs (Scheifes et al., 2016; Zaal et al., ). Medication reviews can be 
time triggered or triggered by care staff observations of medication 
side effects.
In people with intellectual disabilities, antipsychotics are com‐
monly prescribed off‐label, mostly for behavioural problems, such as 
aggression or agitation. Studies in both community (17%–27%) and 
residential (32%–56%) settings have shown that the prevalence of 
antipsychotics use in people with intellectual disabilities is high and 
off‐label use should be identified as an MRP (de Kuijper et al., 2010; 
Sheehan et al., 2015). Clarifying indications by using medication re‐
views could be the solution to reduce off‐label prescribing.
4.3.2 | Reduction of MRPs
This review found that similar benefits from medication reviews are 
seen in people with intellectual disabilities as in the general popu‐
lation. Medication reviews can lead to interventions which reduce 
MRPs, polypharmacy and optimization of medication use.
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4.4 | Health outcomes
The ultimate goal of medication reviews is to improve the health and 
quality of life of people with intellectual disabilities. However, none 
of the studies were designed to measure the effect of the medica‐
tion reviews in terms of health outcomes or improvements of quality 
of life. Most of the studies did not measure long‐term benefits. None 
of the studies described improvements of patient well‐being as a re‐
sult of medication adjustments following a medication review. It is 
therefore recommended to assess this in future studies.
4.5 | Cost of medication reviews (costs of team, 
reduction medication costs and reduction in costs 
caused by MRPs)
Medication reviews should be based on a justifiable cost–benefit 
analysis. Medication reviews in some studies in older people and 
general practice appear to be cost‐effective, with improved patient 
well‐being at reduced cost (Pacini, Smith, Wilson, & Holland, 2007; 
Sorensen et al., 2004). None of the included studies included a cost–
benefit analysis. One study (McKee, 1994) reported reduced cost 
for client medication, but this study did not measure the costs of the 
medication reviews themselves or the effects on patient well‐being. 
Another pilot study (Zaal et al., 2016) could not find conclusive evi‐
dence that medication reviews were cost‐effective for identification 
and reduction of MRPs.
Two studies (Berchou, 1982; McKee, 1994) used education pro‐
grammes during the medication reviews to update the expertise of 
the caregivers in medication therapy. Caregivers recognizing side 
effects could improve early signalling and optimizing medication 
therapy in care facilities for the elderly and people with intellectual 
disabilities. Education is expected it to be cost‐effective in the long 
term for this population (O'Dwyer et al., 2015; Roberts et al., 2001).
In some studies in elderly and general practice settings, medi‐
cation reviews have been found to be cost‐effective (Pacini et al., 
2007; Sorensen et al., 2004), with improved patient well‐being at re‐
duced cost. Future studies are needed to also assess cost‐effective‐
ness of medication reviews in people with intellectual disabilities.
4.6 | Medication review and national policy
Policies to support the monitoring and reduction of polypharmacy 
for people with intellectual disabilities are currently in development. 
Medication reviews are also seen as an important tool by health 
policymakers.
In the Netherlands, there is a lot of attention for appropriate 
medication use. The Ministry of Public Health, Well‐being and Sport 
is working on reducing off‐label prescribing of psychotropic medica‐
tions for people living in residential settings (van Rijn, 2016). Also a 
“Multidisciplinary Guideline Problem Behavior in Adults with intel‐
lectual disabilities” is being developed in the Netherlands, which in‐
cludes guidelines on prescription of psychotropic medications. This 
guideline is scheduled to be implemented in 2019.
Other countries already have implemented guidelines for reduc‐
ing medication use. In 2016, the Royal College of Psychiatrists in the 
United Kingdom published a guideline for prescribing psychotro‐
pic medications for people with intellectual disabilities (The Royal 
College of Psychiatrists, 2016).
In the United Kingdom, there is also a large‐scale project for 
stopping over medication for people with intellectual disabilities, au‐
tism or both (STOMP) (NHS England, 2018). Many different medical 
and non‐medical organizations pledge to work together to find non‐
medication therapies and practical ways of supporting people with 
intellectual disabilities.
All these national policies call for awareness and a change of cul‐
ture in order to reduce psychotropic medications use.
Medication reviews are recommended or even required as an ef‐
fective tool to reduce inappropriate medication use.
4.7 | Limitations
Very few studies are published regarding the effect of medication 
reviews on the identification and reduction of MRPs in people with 
intellectual disabilities. Additionally, the scope of the included stud‐
ies in this review was diverse and the sample size in most of the stud‐
ies was small. The studies did not explicitly address health outcomes 
after the interventions that were performed based on the findings 
in the medication reviews. There are no known clinical randomized 
controlled or controlled prospective trial studies for this review to 
include. In conclusion, there is insufficient evidence to determine 
whether the use of medication reviews significantly leads to a re‐
duction of MRPs and prescribing errors.
4.8 | Final comments and recommendations
Polypharmacy is a common problem among people with intellectual 
disabilities with a high risk of MRPs. Optimization of the quality of 
pharmacotherapy is recommended. This review found that multi‐
disciplinary medication reviews can be used to identify and reduce 
MRPs. However, there is a lack of studies that study the effect and 
impact on different health outcomes and cost‐effectiveness of this 
tool in people with intellectual disabilities.
Regular medication reviews should be part of medical policy to 
optimize medication management in residential settings for people 
with intellectual disabilities. However, future studies are necessary 
to determine the best fitting medication review procedure and fre‐
quency for people with intellectual disabilities in different care 
settings, sub groups and available health professionals for the multi‐
disciplinary teams. Scientific evidence is needed regarding effective‐
ness of systematic medication reviews on health outcomes and costs.
Future long‐term studies would be needed to determine:
1. If the identification of MRPs leads to adjustment of medication 
regime.
2. If the suggested medication interventions lead to long‐term im‐
plementation of the adjustments.
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3. If the medication adjustments lead to improved health conditions 
and well‐being.
4. If different groups can be identified with different levels of health 
benefits resulting from medication reviews (e.g., groups with 
polypharmacy or groups with psychopharmaca). Cost–benefit 
analysis may also differ between groups.
In other populations, medication reviews are used to optimize the 
medication regime with a good result (Holland et al., 2008; Lenander et 
al., 2014; Rubio‐Valera et al., 2014; Vinks et al., 2009; Wolf et al., 2015).
Medication reviews are potentially a good tool for clinicians to 
raise awareness of excessive medication use in people with intellec‐
tual disabilities. Based on medication reviews, potential MRPs may 
be reduced. Randomized clinical trials concerning health outcomes 
with long‐term follow‐up are needed to demonstrate the exact ben‐
efits of medication reviews as a standard intervention tool for peo‐
ple with intellectual disabilities.
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APPENDIX 1
LITER ATURE RE VIE W AMAL NABHANIZ ADEH 7 
AUGUS T 2017
Embase.com 358 352
Medline ovid 177 33
Web‐of‐science 172 51
Cochrane 10 2
psycINFO ovid 213 100
Cinahl ebsco 147 74
Google scholar 200 147
Total 1277 759
Embase.com
('intellectual impairment'/de OR 'mental deficiency'/exp OR 'devel‐
opmental disorder'/de OR 'learning disorder'/exp OR (((mental* OR 
intel* OR learning*) NEAR/3 (defic* OR disab* OR retard* OR handi‐
cap* OR impair* OR defect* OR dysfunction*)) OR ((development* 
OR learning*) NEAR/3 (disorder* OR disab* OR retard*))):ab,ti) AND 
('medication therapy management'/exp OR ((drug* NEAR/3 (utiliza‐
tion* OR use OR usage) NEAR/3 (review* OR evaluat* OR manag* 
OR audit*)) OR ((medication* OR prescrib* OR prescrip*) NEAR/3 
(review* OR evaluat* OR manag* OR audit*))):ab,ti)
Medline ovid
(exp "Intellectual Disability"/ OR "Developmental Disabilities"/ OR 
"Learning Disorders"/ OR (((mental* OR intel* OR learning*) ADJ3 
(defic* OR disab* OR retard* OR handicap* OR impair* OR defect* 
OR dysfunction*)) OR ((development* OR learning*) ADJ3 (disorder* 
OR disab* OR retard*))).ab,ti.) AND ("Medication Therapy 
Management"/ OR "Drug Utilization Review"/ OR ((drug* ADJ3 (uti‐
lization* OR "use" OR usage) ADJ3 (review* OR evaluat* OR manag* 
OR audit*)) OR ((medication* OR prescrib* OR prescrip*) ADJ3 (re‐
view* OR evaluat* OR manag* OR audit*))).ab,ti.)
psycINFO ovid
(exp "Intellectual Development Disorder"/ OR "Developmental 
Disabilities"/ OR "Learning Disorders"/ OR (((mental* OR intel* OR 
learning*) ADJ3 (defic* OR disab* OR retard* OR handicap* OR im‐
pair* OR defect* OR dysfunction*)) OR ((development* OR learning*) 
ADJ3 (disorder* OR disab* OR retard*))).ab,ti.) AND ("Utilization 
Reviews"/ OR ((drug* ADJ3 (utilization* OR "use" OR usage) ADJ3 
(review* OR evaluat* OR manag* OR audit*)) OR ((medication* OR 
prescrib* OR prescrip*) ADJ3 (review* OR evaluat* OR manag* OR 
audit*))).ab,ti.)
Cinahl ebsco
(MH "Intellectual Disability+" OR MH "Developmental Disabilities" 
OR MH "Learning Disorders" OR (((mental* OR intel* OR learning*) 
N2 (defic* OR disab* OR retard* OR handicap* OR impair* OR de‐
fect* OR dysfunction*)) OR ((development* OR learning*) N2 (disor‐
der* OR disab* OR retard*)))) AND (MH "Utilization Review+" OR 
((drug* N2 (utilization* OR "use" OR usage) N2 (review* OR evaluat* 
OR manag* OR audit*)) OR ((medication* OR prescrib* OR prescrip*) 
N2 (review* OR evaluat* OR manag* OR audit*))))
Cochrane
((((mental* OR intel* OR learning*) NEAR/3 (defic* OR disab* OR re‐
tard* OR handicap* OR impair* OR defect* OR dysfunction*)) OR 
((development* OR learning*) NEAR/3 (disorder* OR disab* OR 
retard*))):ab,ti) AND (((drug* NEAR/3 (utilization* OR use OR usage) 
NEAR/3 (review* OR evaluat* OR manag* OR audit*)) OR ((medica‐
tion* OR prescrib* OR prescrip*) NEAR/3 (review* OR evaluat* OR 
manag* OR audit*))):ab,ti)
Web‐of‐science
TS=(((((mental* OR intel* OR learning*) NEAR/2 (defic* OR disab* OR 
retard* OR handicap* OR impair* OR defect* OR dysfunction*)) OR 
((development* OR learning*) NEAR/2 (disorder* OR disab* OR re‐
tard*)))) AND (((drug* NEAR/2 (utilization* OR use OR usage) NEAR/2 
(review* OR evaluat* OR manag* OR audit*)) OR ((medication* OR 
prescrib* OR prescrip*) NEAR/2 (review* OR evaluat* OR manag* 
OR audit*)))))
Google scholar
"mentally|mental|intellectually|intellectual deficit|disabled|disability
|disabilities|retardation|retarded|handicap|handicapped|impaired"|"
developmental|development|learning disorder" "drug utilization|use 
review|evaluation"|"medication review|evaluation"
